August 01, 2019
Years published: 1986, 1990, 1994, 2000, 2003, 2007, 2019
NORD gratefully acknowledges Tina Kushary, MMSc, NORD Editorial Intern from the Emory University Genetic Counseling Training Program and Cecelia A. Bellcross, PhD, MS, CGC, Associate Professor, Director, Genetic Counseling Training Program, Emory University School of Medicine, for assistance in the preparation of this report.
Antley-Bixler syndrome is a rare genetic disorder that can cause structural changes of the skull, bones of the face and other skeletal abnormalities. The disorder is typically associated with premature closure of joints (cranial sutures) between particular bones of the skull (craniosynostosis). Many affected infants and children also may have a prominent forehead, underdeveloped midfacial regions (midfacial hypoplasia), protruding eyes (proptosis), and low-set ears.
Additional skeletal abnormalities are usually present, such as fusion of certain bones of the arms (e.g., radiohumeral or radioulnar synostosis), long, thin fingers and toes (arachnodactyly), and bowing of the thigh bones. In addition, certain joints in the arms and legs may become permanently flexed or extended in fixed postures (joint contractures), resulting in restricted movements.
Antley-Bixler syndrome can be caused by changes (mutations) in the POR gene and the FGFR2 gene.
Antley-Bixler syndrome is typically characterized by structural changes of the skull, bones of the face and other skeletal abnormalities. In most affected infants, there is premature closure of the joints (sutures) between different portions of the skull (craniosynostosis) Additional craniofacial abnormalities may include a large, prominent forehead (frontal bossing), underdeveloped middle regions of the face (midfacial hypoplasia); a large nose with a low nasal bridge; protruding eyes (proptosis); and low-set, malformed (dysplastic) ears.
Antley-Bixler syndrome is also characterized by other distinctive skeletal changes. These may include fusion of bones of the arms that are next to each other (adjacent), particularly the forearm bone on the thumb side of the arm (radius) and the long bone of the upper arm (radiohumeral synostosis). In addition, there can be permanent flexion or extension of certain joints in a fixed position (joint contractures), leading to limited movements of the fingers, wrists, ankles, knees, and/or hips. Affected individuals may also have unusually long, thin fingers and toes (camptodactyly), structural changes on the bottom of the feet (“rocker-bottom” feet); or bowing and/or fractures of the thigh bones.
In some affected infants, a bony or thin layer of tissue may block the passageway between the nose and throat (choanal stenosis or atresia), leading to difficulty breathing. If this symptom is not treated promptly early in life, it may cause life-threatening respiratory problems.
Some individuals with Antley-Bixler syndrome may have additional symptoms. These may include certain structural defects of the urinary and genital organs (urogenital defects), inability to produce cholesterol from steroids (impaired steroidogenesis), developmental delay, and intellectual disability. ABS1 is the name given to the subtype that includes genital anomalies and disordered steroidogenesis. ABS1 is also a severe form of cytochrome P450 oxidoreductase deficiency. ABS2 is the name given to the subtype that does not include genital anomalies and disordered steroidogenesis.
Antley-Bixler syndrome can be caused by mutations in two different genes. ABS1 is associated with mutations in the POR gene and is inherited in an autosomal recessive pattern. This means that a person will have ABS1 when he or she inherits two non-working copies of the POR gene, one from each parent. If an individual receives one working copy of the gene and one not working copy of the gene, the person will be a carrier for the syndrome but will not show symptoms. When both parents are carriers for the syndrome, there is a 25 percent chance the child will have ABS1. Additionally, there is fifty percent chance their child will be carriers of the condition (just like their parents) and a twenty-five percent chance that their child will receive both working copies of the gene. The risk is the same for each pregnancy.
ABS2 is associated with mutations in the FGFR2 gene. In this subtype, the condition is thought to be caused by spontaneous (new) changes of the gene. The condition then may be transmitted in an autosomal dominant pattern in subsequent generations. Dominant genetic disorders occur when only a single copy of a non-working gene is necessary to cause a particular disease. The non-working gene can be inherited from either parent or can be the result of a mutated gene in the affected individual. The risk of passing the non-working gene from an affected parent to an offspring is 50% for each pregnancy. The risk is the same for males and females.
It is important to note that there are a number of syndromes that have been identified which are associated with mutations of the FGFR2 gene including Apert, Crouzon, and Pfeiffer syndromes. (For further information on these disorders, please see the “Related Disorders” section of this report below.)
There have been a few reported cases which show that symptoms similar to Antley-Bixler syndrome may have resulted from maternal use of the antifungal medication (fluconazole) during early pregnancy. There is not a lot of research showing why this medication causes symptoms similar to Antley-Bixler syndrome.
This condition has been described in over 30 patients to date. The estimated prevalence for the condition is less than 1 in 1,000,000.
The diagnosis of Antley-Bixler syndrome is usually made after birth (postnatally) based upon a thorough clinical evaluation and characteristic physical findings. Other imaging procedures and genetic testing may also be conducted to diagnose the disorder.
In some children, a diagnosis of Antley-Bixler syndrome may be suggested before birth (prenatally) based upon test such as ultrasound. Ultrasound allows us to generate an image of the developing fetus, which may then reveal characteristic findings that are associated with the disorder. If there is a known family history of the condition, targeted genetic testing is available for patient families.
The treatment of Antley-Bixler syndrome is directed toward the specific symptoms that are seen in each individual. Such treatment requires the coordinated efforts of a team of medical professionals who may need to systematically and comprehensively plan the treatment for a child with this condition. These professionals may include pediatricians, surgeons, physicians who specialize in disorders of specific body areas and organs. In individuals with Antley-Bixler syndrome, treatment typically includes surgery. The surgical procedures performed will depend upon the severity of the skeletal problems and its associated symptoms. It is possible that multiple surgeries will be needed in order to treat the malformations present.
There is no cure for the condition. All treatment is supportive and aimed at managing symptoms. However, early intervention may be important in ensuring that affected children reach their potential. For example, physical therapy is typically recommended to help improve the range of movement at certain joint contractures. Other therapies that may aide in managing symptoms include occupational therapy and speech therapy.
Because this is a genetic condition, individuals with Antley-Bixler syndrome and their families would benefit from meeting with a genetic counselor. Genetic counselors are professionals who have specialized education in genetics and counseling to provide personalized help patients may need as they make decisions about their genetic health.
Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/ All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
For information about clinical trials sponsored by private sources, contact: http://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/
Gorlin RJ, et al., eds. Syndromes of the Head and Neck. 7th ed. New York, NY; Oxford University Press; 2013.
Yauy K, Mau-Them FT, Willems M, et al. B3GAT3-related disorder with craniosynostosis and bone fragility due to a unique mutation. Genetics in Medicine. 2017;20(2):269-274. doi:10.1038/gim.2017.109
Oldani E, Gare C, Bucourt M and Carbillon L. Prenatal diagnosis of Antley-Bixler syndrome and POR deficiency. American Journal of Case Reports. 2015; 16: 882–885.
McGlaughlin KL, Witherow H, Dunaway DJ, David DJ, Anderson PJ. Spectrum of Antley-Bixler syndrome. Journal of Craniofacial Surgery. 2010;21(5):1560-1564. doi:10.1097/scs.0b013e3181ec6afe.
Idkowiak J, Cragun D, Hopkin RJ, et al. Cytochrome P450 Oxidoreductase Deficiency. 2005 Sep 8 [Updated 2017 Aug 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1419/ Accessed May 9, 2019.
Robin NH, Falk MJ, Haldeman-Englert CR. FGFR-Related Craniosynostosis Syndromes. 1998 Oct 20 [Updated 2011 Jun 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1455/ Accessed May 9, 2019.
Antley Bixler syndrome. Orphanet. Last update: January 2007. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=83. Accessed May 9, 2019.
Cytochrome P450 oxidoreductase deficiency – Genetics Home Reference – NIH. U.S. National Library of Medicine.Reviewed March 2014. https://ghr.nlm.nih.gov/condition/cytochrome-p450-oxidoreductase-deficiency. Accessed May 9, 2019.
Online Mendelian Inheritance in Man, OMIM (TM). John Hopkins University, Baltimore, MD. MIM Number 207410; Updated 04/24/2012Available at: https://www.omim.org/entry/207410 Accessed May 9, 2019.
Online Mendelian Inheritance in Man, OMIM (TM). John Hopkins University, Baltimore, MD. MIM Number 201750; 09/07/2016. Available at: https://www.omim.org/entry/201750?search=201750&highlight=201750 Accessed May 9, 2019.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.Learn more http://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/
Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.Learn more http://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/
This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.Learn more http://rarediseases.org/patient-assistance-programs/caregiver-respite/
Powered by NORD, the IAMRARE Registry Platform® is driving transformative change in the study of rare disease. With input from doctors, researchers, and the US Food & Drug Administration, NORD has created IAMRARE to facilitate patient-powered natural history studies to shape rare disease research and treatments. The ultimate goal of IAMRARE is to unite patients and research communities in the improvement of care and drug development.